PMID- 31171473
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20200806
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 19
IP  - 8
DP  - 2019 Aug
TI  - Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern 
      Treatment and FISH Analysis.
PG  - e470-e477
LID - S2152-2650(19)30143-0 [pii]
LID - 10.1016/j.clml.2019.04.011 [doi]
AB  - BACKGROUND: The Revised International Staging System (R-ISS) has been widely 
      adopted to prognosticate multiple myeloma. As a result, the continued utility of 
      conventional metaphase karyotyping has been called into question. PATIENTS AND 
      METHODS: A multi-center study for newly diagnosed patients with multiple myeloma 
      who received novel agent(s) at induction was conducted. Conventional metaphase 
      karyotype information was categorized based on ploidy. We evaluated the impact of 
      ploidy on overall survival (OS) including multivariate analysis, taking into 
      account the R-ISS stages, transplant status, age, and novel agent(s) used at 
      induction. We also evaluated if it is possible to identify high-risk (HR) 
      patients with conventional karyotyping when a fluorescence in situ hybridization 
      analysis is not available. Results were validated in an independent cohort. 
      RESULTS: There were 308 patients evaluable. Ploidy significantly affected the OS 
      of patients with R-ISS stage II, with non-hyperdiploid patients doing the worst. 
      In the multivariate analysis, ploidy was significantly associated with OS. R-ISS 
      stage II patients with or without non-hyperdiploid karyotype had significantly 
      different survival. We replaced HR fluorescence in situ hybridization 
      abnormalities with HR metaphase karyotypic abnormalities (non-hyperdiploid 
      karyotype). When compared with R-ISS, there was a high level of concordance in HR 
      patients identified using HR karyotypic abnormalities. These results were 
      validated with an independent cohort of 375 patients. CONCLUSION: Conventional 
      metaphase karyotyping is an independent prognostic factor even in the setting of 
      R-ISS.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Soekojo, Cinnie Yentia
AU  - Soekojo CY
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore.
FAU - Wang, Guo-Miao
AU  - Wang GM
AD  - Peking University Institute of Hematology, Beijing, China.
FAU - Chen, Yunxin
AU  - Chen Y
AD  - Department of Hematology, Singapore General Hospital, Singapore, Singapore.
FAU - Casan, Joshua
AU  - Casan J
AD  - Alfred Hospital, Melbourne, Victoria, Australia.
FAU - Wolyncewicz, Grace
AU  - Wolyncewicz G
AD  - Alfred Hospital, Melbourne, Victoria, Australia.
FAU - Lin, Adeline
AU  - Lin A
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore.
FAU - Poon, Li Mei
AU  - Poon LM
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore.
FAU - de Mel, Sanjay
AU  - de Mel S
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore.
FAU - Koh, Liang Piu
AU  - Koh LP
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore.
FAU - Tan, Lip Kun
AU  - Tan LK
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore.
FAU - Ooi, Melissa G
AU  - Ooi MG
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore.
FAU - Nagarajan, Chandramouli
AU  - Nagarajan C
AD  - Department of Hematology, Singapore General Hospital, Singapore, Singapore.
FAU - Liu, Yang
AU  - Liu Y
AD  - Peking University Institute of Hematology, Beijing, China.
FAU - Lai, Yue-Yun
AU  - Lai YY
AD  - Peking University Institute of Hematology, Beijing, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Peking University Institute of Hematology, Beijing, China.
FAU - Spencer, Andrew
AU  - Spencer A
AD  - Alfred Hospital, Melbourne, Victoria, Australia.
FAU - Gopalakrishnan, Sathish Kumar
AU  - Gopalakrishnan SK
AD  - Department of Hematology, Singapore General Hospital, Singapore, Singapore.
FAU - Lu, Jin
AU  - Lu J
AD  - Peking University Institute of Hematology, Beijing, China. Electronic address: 
      jin1lu@sina.com.
FAU - Chng, Wee Joo
AU  - Chng WJ
AD  - National University Cancer Institute, National University Health System, 
      Singapore, Singapore; Cancer Science Institute of Singapore, National University 
      of Singapore, Singapore, Singapore; Department of Medicine, Yong Loo Lin School 
      of Medicine, National University of Singapore, Singapore, Singapore. Electronic 
      address: mdccwj@nus.edu.sg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190428
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
SB  - IM
MH  - Aged
MH  - *Chromosome Aberrations
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Hematopoietic Stem Cell Transplantation/*mortality
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Karyotyping/*methods
MH  - Male
MH  - Multiple Myeloma/genetics/*pathology/therapy
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - Chromosomal abnormalities
OT  - Cytogenetics
OT  - Myeloma
OT  - Prognosis
OT  - Survival
EDAT- 2019/06/07 06:00
MHDA- 2020/08/07 06:00
CRDT- 2019/06/08 06:00
PHST- 2019/02/02 00:00 [received]
PHST- 2019/04/09 00:00 [revised]
PHST- 2019/04/19 00:00 [accepted]
PHST- 2019/06/07 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
PHST- 2019/06/08 06:00 [entrez]
AID - S2152-2650(19)30143-0 [pii]
AID - 10.1016/j.clml.2019.04.011 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e470-e477. doi: 
      10.1016/j.clml.2019.04.011. Epub 2019 Apr 28.